Business briefs: Quintiles and Forest, plus Paula Watch

Share this article:

Quintiles has purchased CRO Novella Clinical. The deal will bring Novella's oncology, medical device and diagnostic trials into the Quintiles portfolio, but Novella will operate as a stand-alone unit.

Forest and Almirall are delaying an experimental COPD drug submission to the FDA. The drug is a combination of two bronchodilators, and the companies said in a statement Thursday that in pre-NDA discussions with the FDA, that the regulator had questions about “resolving chemistry, manufacturing and control specifications.” The two-for-one drug combines aclidinum bromide, known by the brand name Tudorza, and formoterol fumarate.

Paula Watch: Paula Deen's rebound may have begun. One day after a judge threw out racism claims against the former Food Network star, Savannahnow.com reports that the celebrity chef may have a cameo on her son's show "Home for Dinner with Jamie Deen." Savannahnow.com notes that it is unclear if the episode was filmed before Deen's reputation began to plummet.
Share this article:

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.